Thyroid Function in Egyptian Children with Sickle Cell Anemia in Correlation with Iron Load

Author(s): Adel A. Hagag*, Hassan M. El-Asy, Ibrahim M. Badraia, Nahed M. Hablas, Amal Ezzat Abd El-Latif.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 19 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Sickle Cell Disease (SCD) is characterized by defective hemoglobin synthesis, hemolytic anemia, frequent thrombosis and chronic organ damage including endocrine organs.

Aim: To assess thyroid function in children with SCD in correlation and iron load.

Patients and Method: This study was conducted on 40 children with SCD with iron overload (serum ferritin more than 1000 ng/ml) including 22 males and 18 females with their ages ranging from 11-14 years and mean age value of 11.63±1.36 years and 40 healthy children of matched age and sex as a control group. For all patients; complete blood count, hemoglobin electrophoresis, serum ferritin, serum iron, iron binding capacity and thyroid function including Free Thyroxine (FT4), Free Triiodothyronine (FT3), Thyroid Stimulating Hormone (TSH), Thyroid Peroxidase Antibody (TPOAb) and Thyroglobulin Antibody (TgAb) were done.

Results: Significantly higher serum ferritin and iron and significantly lower Total Iron Binding Capacity (TIBC) were found in patients compared with controls (mean serum ferritin was 1665.2±1387.65ng/ml in patients versus 192.55±107.2ng/ml in controls with p-value of 0. 007, mean serum iron was 164±83.9 ug/dl in patients versus 89.5±4.5ug/dl in controls with p-value of 0.039, mean TIBC was 238±44.5ug/dl in patients versus 308±11ug/dl in controls with p-value of 0.001). Significantly higher serum TSH and significantly lower Free T3 and Free T4 were found in patients compared with controls with no significant correlation between thyroid hormones and serum ferritin (mean serum TSH was 4.61±1.2 µIU/mL in patients versus 2.11 ± 0.54 µIU /mL in controls with p-value of 0. 045, mean serum FT3 was 2.61 ±1.3 pg/mL versus 3.93±0.47pg/mL in controls with p-value of 0.027, mean serum FT4 was 0.91±0.174 ng/dL versus 1.44± 0.164 ng/dLin controls with p-value of 0.047, r = - 0. 008 and p-value was 0. 973 for correlation between free T4 and serum ferritin, r = -0. 028 and p-value was 0. 9 for correlation between TSH and serum ferritin and r= - 0.259 and p-value was 0.27 for correlation betweenT3 and serum ferritin). There were no significant differences between patients and controls regarding thyroid peroxidase antibody and thyroglobulin antibody (mean serum thyroid peroxidase antibody was 22.45± 4.32 in patients versus 22.45 ± 3.21 in controls with p-value of 0.98 while mean serum thyroglobulin antibody was 12.32 ± 2.65 in patients versus 12.99 ± 2.34 in controls with p-value of 0.76.

Conclusion: Thyroid hormones deficiency may occur in some patients with SCD.

Recommendations: Regular assessment of thyroid function in children with SCD may be recommended as they are more vulnerable to develop hypothyroidism and may require replacement therapy.

Keywords: Sickle cell disease, thyroid function, hypothyroidism, iron overload, Thyroid Stimulating Hormone (TSH), Red Blood Cells (RBCs).

[1]
Vanderhave, K.L.; Perkins, C.A.; Scannell, B.; Brighton, B.K. orthopaedic manifestations of sickle cell disease. J. Am. Acad. Orthop. Surg., 2018, 26(3), 94-101.
[2]
Piel, F.B.; Patil, A.P.; Howes, R.E.; Nyangiri, O.A.; Gething, P.W.; Dewi, M.; Temperley, W.H.; Williams, T.N.; Weatherall, D.J.; Hay, S.I. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet, 2013, 381(9861), 142-151.
[3]
Ansari, J.; Moufarrej, Y.E.; Pawlinski, R.; Gavins, F.N.E. Sickle cell disease: A malady beyond a hemoglobin defect in cerebrovascular disease. Expert Rev. Hematol., 2018, 11(1), 45-55.
[4]
Rees, D.C.; Williams, T.N.; Gladwin, M.T. Sickle-cell disease. Lancet, 2010, 376(9757), 2018-2031.
[5]
El-Hazmi, M.A.; Bahakim, H.M.; al-Fawaz, I. Endocrine functions in sickle cell anemia patients. J. Trop. Pediatr., 1992, 38, 307-313.
[6]
Mandese, V.; Marotti, F.; Bedetti, L.; Bigi, E.; Palazzi, G.; Iughetti, L. Effects of nutritional intake on disease severity in children with sickle cell disease. Nutr. J., 2016, 15(1), 46.
[7]
Khan, A.D.; Cheema, N.A.; Anwar, M. Endocrine dysfunction in beta-thalassemia major patients at Rawalpindi, Pakistan. HealthMED., 2010, 4(3), 580-585.
[8]
George-Gay, B.; Parker, K. Understanding the complete blood count with differential. J. Perianesth. Nurs., 2003, 18(2), 96-114. [9]Schneider, R.G.; Hightower, B.; Hosty, T.S.; Ryder, H.; Tomlin, G.; Atkins, R.; Brimhall, B.; Jones, R.T. Abnormal hemoglobins in a quarter million people. Blood, 1976, 84(5), 629-637.
[10]
Beard, J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J. Nut.,, 2001, 131(2S-2), 568S- 580S.
[11]
Kuvibidila, S.; Yu, L.; Warrier, R.P.; Ode, D.; Mbele, V. Usefulness of serum ferritin levels in the assessment of iron status in non-pregnant Zairean women of childbearing age. J. Trop. Med. Hyg., 1994, 97(3), 171-179.
[12]
Shivaraj, G.; Prakash, B.D.; Sonal, V.; Shruthi, K.; Vinayak, H.; Avinash, M. Thyroid function tests: A review. Eur. Rev. Med. Pharmacol. Sci., 2009, 13(5), 341-349.
[13]
Alnaqdy, A.; Al-Maskari, M. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with graves’ disease. Med. Princ. Pract., 2005, 14(4), 209-212.
[14]
Dubey, P.; Sudha, S.; Ankit, P. Deferasirox: The new oral iron chelator. Indian Pediatr., 2007, 44(8), 603-607.
[15]
Hoffbrand, A.V.; Taher, A.; Cappellini, M.D. How I treat transfusional iron overload. Blood, 2012, 120(18), 3657-3669.
[16]
Gladwin, M.T. Cardiovascular complications in patients with sickle cell disease. Hematology (Am. Soc. Hematol. Educ. Program), 2017, 2017(1), 423-430.
[17]
Steinberg, M.H. Sickle cell anemia, the first molecular disease: Overview of molecular etiology, pathophysiology, and therapeutic approaches. Sci. World J., 2008, 8, 1295-1324.
[18]
Sadarangani, M.; Julie Makani, J.; Komba, A.N.; Thomas, N.W. An observational study of children with sickle cell disease in Kilifi, Kenya. Br. J. Haematol., 2009, 146(6), 675-682.
[19]
Barden, E.M.; Kawchak, D.A.; Ohene-Frempong, K.; Stallings, V.A.; Zemel, B.S. Body composition in children with sickle cell disease. Am. J. Clin. Nutr., 2002, 76, 218-225.
[20]
Adegoke, S.A.; Figueiredo, M.S.; Adekile, A.D.; Braga, J.A.P. Comparative study of the growth and nutritional status of Brazilian and Nigerian school-aged children with sickle cell disease. Int. Health, 2017, 9(6), 327-334.
[21]
Serjeant, G.R.; Serjeant, B.E. The gut and the abdomen. In: Serjeant GR and Serjeant BE (eds). Sickle cell disease. 3rd ed. New York: Oxford University Press,, 2001, 189-193.
[22]
Catanzaro, T.; Koumbourlis, A.C. Somatic growth and lung function in sickle cell disease. Paediatr. Respir. Rev., 2014, 15(1), 28-32.
[23]
Hagag, A.A.; El-Farargy, M.S.; Elrefaey, S. Abo El-enein, A.M.Study of gonadal hormones in Egyptian female children with sickle cell anemia in correlation with iron overload: Single center study. Hematol. Oncol. Stem Cell Ther., 2016, 9(1), 1-7.
[24]
Ballas, S.K.; Marcolina, M.J. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion, 2006, 46, 105-110.
[25]
Babadoko, A.A.; Ibinaye, P.O.; Hassan, A.; Yusuf, R.; Ijei, I.P.; Aiyekomogbon, J.; Aminu, S.M.; Hamidu, A.U. Autosplenectomy of sickle cell disease in Zaria, Nigeria: An ultrasonographic assessment. Oman Med. J., 2012, 27(2), 121-123.
[26]
Ahmed, S.G.; Ibrahim, U.A.; Hassan, A.W. Hematological parameters in sickle cell anemia patients with and without priapism. Ann. Saudi Med., 2006, 26, 439-443.
[27]
Akodu, S.O.; Diaku-Akinwumi, I.N.; Kehinde, O.A.; Njokanma, O.F. Serum iron status of under-five children with sickle cell anemia in Lagos, Nigeria. Anemia, 2013, 2013, 254765.
[28]
Akinbami, A.A.; Dosunmu, A.O.; Adediran, A.A.; Oshinaike, O.O.; Osunkalu, V.O.; Ajibola, S.O.; Arogundade, O.M. Serum ferritin levels in adults with sickle cell disease in Lagos, Nigeria. J. Blood Med., 2013, 4, 59-63.
[29]
Patra, P.K.; Khodiar, P.K.; Sumanta, P. Nupur, Srivastava. Study of serum ferritin, iron & total Iron binding capacity in sickle cell disease. J. Adv. Res. Biol. Sci., 2012, 4(4), 340-344.
[30]
Cohen, A.R.; Galanello, R.; Pennell, D.J.; Cunningham, M.J.; Vichinsky, E. Thalassemia. Hematol. Am. Soc. Hematol. Educ. Prog., 2004, 14-34.
[31]
El-Sarraf, N.A.; Sulaiman, A.M.; Mansour, H. Endocrine disorder in patients with sickle cell anemia. Benha Med. J., 2009, 26(2), 467-468.
[32]
Ozen, S.; Unal, S.; Ercetin, N.; Taşdelen, B. Frequency and risk factors of endocrine complications in Turkish children and adolescents with sickle cell anemia. Turk J. Hematol.,2013, 30(1), 25-31. [33]Karazincir, S.; Balci, A.; Yonden, Z.; Gali, E.; Daplan, T.; Beyoglu, Y.; Kaya, H.; Egilmez, E. Thyroid doppler indices in patients with sickle cell disease. Clin. Imaging, 2013, 37(5), 852-855.
[34]
Smiley, D.; Dagogo-Jack, S.; Umpierrez, G. Therapy Insight: Metabolic and endocrine disorders in sickle-cell disease. Nat. Clin. Pract. Endocrinol. Metab., 2008, 4(2), 102-109.
[35]
Rhodes, M.; Akohoue, S.A.; Shankar, S.M.; Fleming, I.; Qi , An. A.; Yu, C.; Acra, S.; Buchowski, M.S. Growth patterns in children with sickle cell anemia during puberty. Pediatr. Blood Cancer, 2009, 53(4), 635-641.
[36]
Williams, K.M.; Dietzen, D.; Hassoun, A.A.; Fennoy, I.; Bhatia, M. Autoimmune thyroid disease following Alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease. Pediatr. Blood Cancer, 2014, 61(12), 2307-2309.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 1
Year: 2019
Page: [46 - 52]
Pages: 7
DOI: 10.2174/1871530318666180912153349
Price: $58

Article Metrics

PDF: 17
HTML: 3